A practical guide to management in
primary care
Science bit
Clinical presentation and complications
Investigations
Management
Discussion of guidelines
Mini audit of our patients
Derived from the diet – found in meat, fish,
eggs, milk but not in plants
Up to 2yrs worth are stored in the liver.
Impaired absorption
Pernicious anaemia
Gastrectomy
Ileal disease or resection
Malabsorption syndromes
Low dietary intake
Vegans
Autoimmune disease – antibodies are formed
against the parietal cells. This produces
atrophic gastritis and reduced IF production.
1:8000 of over 60s
F>M
All races but more common in fair skin, blue
eyed people
Associated with other AA diseases –
particularly thyroid diseases, addison’s and
vitiligo
Slow onset – symptoms of anaemia
‘Lemon yellow’ colour due to pallor and mild
jaundice (due to ineffective erythropoiesis)
Glossitis and angular stomatitis
Neurological changes (B12 <60ng/L) (SCDC)
Glove and stocking parasthaesia
Early loss of vibration sense
Progressive weakness and ataxia
Dementia
FBC – Megaloblastic anaemia with
hypersegmented neutrophils.
B12 levels – low
Parietal cell antibodies - +ve in 90%
Bilirubin may be raised
Serum Folate – may be normal or high
Shilling test
Endoscopy – shows atrophic gastric mucosa
B12 Deficiency without neurological
involvement:
1mg Hydroxocobalamin 3 times a week for 2 weeks
then every 3 months.
B12 Deficiency with neurological involvement:
1mg Hydroxocobalamin very other day until no
further improvement then every 2months.
Prodigy (CKS) guidelines
60 patients with ‘Hydroxocobalamin’
prescribed.
Ave age 70yrs (34-95)
58% female 42% male
Do we routinely monitor patients on B12
injections?
Do we consistently give B12 every 3months?
Do we document (or investigate) the cause of
the B12 deficiency?
Monitoring, 24
No monitoring,
36
12
6
2
5
3
3
1
1
No. injections
Te
n
El
ev
en
Tw
el
ve
6
x
Se
ve
rn
Ei
gh
t
Ni
ne
8
Si
4
Tw
o
Th
re
e
Fo
ur
Fi
ve
O
ne
Ze
ro
no. patients
14
12
10
10
7
5
3
2
0
2
5
ie
t
5
?D
al
lb
ow
el
re
se
ct
io
n
Cr
oh
ns
y
ia
re
ct
om
an
ae
m
10
Sm
ou
s
re
co
rd
ed
20
G
as
t
Pe
rn
ici
Ni
l
30
28
25
18
15
5
2
2
0
We’re a bit inconsistent with monitoring.
We’re a bit inconsistent with dosing.
BUT: Does this simply reflect tailoring tests and
doses to patients individual needs?
We should probably pursue the cause of the
B12 deficiency (and document this) more often.